• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endocrinology, Diabetes & Metabolism >The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real‐world data in Israel
【24h】

The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real‐world data in Israel

机译：2型糖尿病患者中胰岛素Glargine 300 u / ml的有效性：以色列的真实数据分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims Randomized controlled trials have shown that insulin glargine 300?U/mL (Gla‐300) has a more stable and prolonged glucose lowering effect among patients with type 2 diabetes (T2DM) compared to insulin glargine 100?U/mL (Gla‐100), resulting in a reduced risk of hypoglycaemia while maintaining a similar efficacy of lowering HbAsub1c/sub. We aimed to investigate if the effectiveness of Gla‐300 is reproducible in real‐world settings. Material and methods In this retrospective cohort study, data from a large state‐mandated health organization were used to identify adult T2DM patients who were previously on insulin and initiated Gla‐300 therapy between 6/ 2016 and 12/2017. Changes in HbAsub1c/sub levels, body weight and insulin dose were calculated from baseline period and over a follow‐up period of 180?days. Documented hypoglycaemia events were also explored. Results A total of 1797 patients were included in this study with a mean age of 64.2 (SD?=?±11.0y), baseline HbAsub1c/sub was 8.7?±?1.6% and 42.5% were females. Among all patients with HbAsub1c/sub measurement during follow‐up (n?=?1508), HbAsub1c/sub was significantly reduced by ?0.6% (95% CI ?0.6,?0.5; P ?.001) from baseline, with a significant reduction in body weight (?0.4?kg; P =? Additionally, a significant ( P =?.04) reduction of 40.5% in patients with hypoglycaemia events was recorded during follow‐up period, from 2.1% (n?=?37) at the baseline period to 1.2% (n?=?22). Conclusions This real‐world study supports evidence from RCTs regarding the effectiveness of Gla‐300 among T2DM patients by improving glycaemic control.
机译：AIMS随机对照试验表明，与胰岛素狼氨酰100〜U / mL（GLA-100（GLA-100）相比，胰岛素冰柱300？U / ml（GLA-300）在2型糖尿病（T2DM）的患者中具有更稳定和长期的葡萄糖降低效果。 ），导致低血糖的风险降低，同时保持降低HBA 1c 的相似疗效。我们旨在调查GLA-300的有效性在现实世界中的可重复性。本回顾性队列研究中的材料和方法，来自大型国家授权的健康组织的数据用于鉴定以前关于胰岛素的成人T2DM患者，并在2016年至2016年和2017年12月12日之间启动GLA-300疗法。 HBA 1c 水平，体重和胰岛素剂量的变化是从基线期间和180℃的后续时间计算的。还探讨了记录的低血糖活动。结果共有1797名患者包含在本研究中，平均年龄为64.2（SD？=±11.0y），基线HBA 1c 为8.7？±1.6％和42.5％是女性。在随访期间的所有HBA 1c的患者中（n？=Δ1508），HBA 1c 被α0.6％显着降低（95％ci？0.6 ,?从基线0.5; p <001），体重显着降低（？0.4 kg; p =？另外，在低血糖事件患者期间记录了40.5％的显着（p = 04）减少了40.5％在基线期间的2.1％（n？= 37）到1.2％（n？= 22）。结论这项现实世界的研究支持来自RCT的证据是T2DM患者中GLA-300的有效性通过改善血糖控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号